PDE1A and acute lymphoblastic leukemia: Specifically, thymoquinone suppresses PDE1A expression and inhibits UHRF1 via a p73-dependent mechanism, suggesting potential application in acute lymphoblastic leukemia (ALL) therapy (Table 1) (27).